N-[2-methyl-5-[5-[4-methyl-3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]phenyl]-4-pyridin-3-ylpyrimidin-2-amine
C26H19F3N6O — CID 127040242
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[2-methyl-5-[5-[4-methyl-3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]phenyl]-4-pyridin-3-ylpyrimidin-2-amine
N-[2-methyl-5-[5-[4-methyl-3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]phenyl]-4-pyridin-3-ylpyrimidin-2-amine (PubChem CID 127040242) has the molecular formula C26H19F3N6O and a molecular weight of 488.47 g/mol. Its IUPAC name is N-[2-methyl-5-[5-[4-methyl-3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]phenyl]-4-pyridin-3-ylpyrimidin-2-amine.
Molecular Properties
| Compound Name | N-[2-methyl-5-[5-[4-methyl-3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]phenyl]-4-pyridin-3-ylpyrimidin-2-amine |
|---|---|
| PubChem CID | 127040242 |
| Molecular Formula | C26H19F3N6O |
| Molecular Weight | 488.47 g/mol |
| Exact Mass | 488.16 |
| IUPAC Name | N-[2-methyl-5-[5-[4-methyl-3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]phenyl]-4-pyridin-3-ylpyrimidin-2-amine |
| SMILES | Cc1ccc(-c2nnc(-c3ccc(C)c(C(F)(F)F)c3)o2)cc1Nc1nccc(-c2cccnc2)n1 |
| InChI | InChI=1S/C26H19F3N6O/c1-15-5-7-17(12-20(15)26(27,28)29)23-34-35-24(36-23)18-8-6-16(2)22(13-18)33-25-31-11-9-21(32-25)19-4-3-10-30-14-19/h3-14H,1-2H3,(H,31,32,33) |
| InChIKey | CJUCDDOYPPKVPW-UHFFFAOYSA-N |
| XLogP | 6.63 |
| TPSA | 89.62 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 488.47 |
| LogP ≤ 5 | 6.63 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 127040242 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.